Dräger expands neonatal care portfolio with BiliPredics software solution
Dräger has expanded its neonatal care portfolio by introducing BiliPredics, a predictive software solution developed by NeoPredics for forecasting bilirubin progression in newborns. The innovative digital application can predict bilirubin levels up to 60 hours in advance, utilizing a database of over 50,000 bilirubin measurements from nearly 10,000 newborns.
The software aims to enhance jaundice management, which affects approximately 50% of all newborns and up to 80% of premature babies. BiliPredics integrates with electronic medical records and aligns with the 2022 AAP Hyperbilirubinemia Guideline, requiring minimal clinical parameters to generate insights.
The solution complements Dräger's existing jaundice management products, including the Jaundice Meter JM-105 for non-invasive measurements and the BiliLux Phototherapy Light for treatment. This comprehensive approach supports enhanced discharge planning and data-driven decision-making in neonatal care.
Dräger ha ampliato il suo portafoglio di cure neonatali introducendo BiliPredics, una soluzione software predittiva sviluppata da NeoPredics per prevedere la progressione della bilirubina nei neonati. Questa innovativa applicazione digitale può prevedere i livelli di bilirubina fino a 60 ore in anticipo, utilizzando un database di oltre 50.000 misurazioni di bilirubina provenienti da quasi 10.000 neonati.
Il software mira a migliorare la gestione dell'ittero, che colpisce circa il 50% di tutti i neonati e fino all'80% dei bambini prematuri. BiliPredics si integra con le cartelle cliniche elettroniche e si allinea con le linee guida AAP sulla iperbilirubinemia del 2022, richiedendo parametri clinici minimi per generare approfondimenti.
La soluzione completa i prodotti esistenti di gestione dell'ittero di Dräger, inclusi il Jaundice Meter JM-105 per misurazioni non invasive e la luce per fototerapia BiliLux per il trattamento. Questo approccio completo supporta una pianificazione delle dimissioni migliorata e decisioni basate sui dati nella cura neonatale.
Dräger ha ampliado su cartera de cuidados neonatales al introducir BiliPredics, una solución de software predictivo desarrollada por NeoPredics para pronosticar la progresión de la bilirrubina en recién nacidos. Esta innovadora aplicación digital puede predecir los niveles de bilirrubina hasta 60 horas antes, utilizando una base de datos de más de 50,000 mediciones de bilirrubina de casi 10,000 recién nacidos.
El software tiene como objetivo mejorar la gestión de la ictericia, que afecta aproximadamente al 50% de todos los recién nacidos y hasta al 80% de los bebés prematuros. BiliPredics se integra con los registros médicos electrónicos y se alinea con la Guía de Hiperbilirrubinemia de la AAP de 2022, requiriendo parámetros clínicos mínimos para generar información.
La solución complementa los productos existentes de gestión de ictericia de Dräger, incluidos el Jaundice Meter JM-105 para mediciones no invasivas y la luz de fototerapia BiliLux para el tratamiento. Este enfoque integral apoya una mejor planificación de altas y la toma de decisiones basada en datos en el cuidado neonatal.
Dräger는 BiliPredics를 도입하여 신생아 치료 포트폴리오를 확장했습니다. 이는 NeoPredics에서 개발한 예측 소프트웨어 솔루션으로, 신생아의 빌리루빈 진행 상황을 예측합니다. 이 혁신적인 디지털 애플리케이션은 거의 10,000명의 신생아로부터 수집된 50,000개 이상의 빌리루빈 측정값을 활용하여 최대 60시간 전에 빌리루빈 수치를 예측할 수 있습니다.
이 소프트웨어는 약 50%의 신생아와 최대 80%의 조산아에게 영향을 미치는 황달 관리를 향상시키는 것을 목표로 합니다. BiliPredics는 전자 의료 기록과 통합되며, 2022년 AAP의 고빌리루빈혈증 가이드라인과 일치하며, 통찰력을 생성하기 위해 최소한의 임상 매개변수를 요구합니다.
이 솔루션은 비침습적 측정을 위한 Jaundice Meter JM-105와 치료를 위한 BiliLux 광치료등을 포함하여 Dräger의 기존 황달 관리 제품을 보완합니다. 이 포괄적인 접근 방식은 신생아 치료에서 퇴원 계획을 개선하고 데이터 기반 의사 결정을 지원합니다.
Dräger a élargi son portefeuille de soins néonatals en introduisant BiliPredics, une solution logicielle prédictive développée par NeoPredics pour prévoir la progression de la bilirubine chez les nouveau-nés. Cette application numérique innovante peut prédire les niveaux de bilirubine jusqu'à 60 heures à l'avance, en utilisant une base de données de plus de 50 000 mesures de bilirubine provenant de près de 10 000 nouveau-nés.
Le logiciel vise à améliorer la gestion de la jaunisse, qui touche environ 50 % de tous les nouveau-nés et jusqu'à 80 % des bébés prématurés. BiliPredics s'intègre aux dossiers médicaux électroniques et s'aligne sur les directives AAP de 2022 concernant l'hyperbilirubinémie, nécessitant des paramètres cliniques minimaux pour générer des informations.
La solution complète les produits existants de gestion de la jaunisse de Dräger, y compris le Jaundice Meter JM-105 pour des mesures non invasives et la lumière de photothérapie BiliLux pour le traitement. Cette approche globale soutient une meilleure planification des sorties et une prise de décision basée sur les données dans les soins néonatals.
Dräger hat sein Portfolio für die neonatalen Pflege erweitert, indem es BiliPredics eingeführt hat, eine prädiktive Softwarelösung, die von NeoPredics entwickelt wurde, um den Bilirubingehalt bei Neugeborenen vorherzusagen. Die innovative digitale Anwendung kann Bilirubinwerte bis zu 60 Stunden im Voraus vorhersagen und nutzt eine Datenbank mit über 50.000 Bilirubinmessungen von fast 10.000 Neugeborenen.
Die Software zielt darauf ab, das Management von Gelbsucht zu verbessern, das etwa 50 % aller Neugeborenen und bis zu 80 % der Frühgeborenen betrifft. BiliPredics integriert sich in elektronische Patientenakten und entspricht den 2022 AAP-Richtlinien zur Hyperbilirubinämie, wobei nur minimale klinische Parameter erforderlich sind, um Erkenntnisse zu gewinnen.
Die Lösung ergänzt die bestehenden Produkte von Dräger zur Gelbsuchtbehandlung, einschließlich des Jaundice Meter JM-105 für nicht-invasive Messungen und des BiliLux Phototherapielichts zur Behandlung. Dieser umfassende Ansatz unterstützt eine verbesserte Entlassungsplanung und datengestützte Entscheidungsfindung in der neonatalen Pflege.
- Introduction of new revenue stream through BiliPredics software solution
- Large-scale validation with 50,000+ bilirubin measurements from 10,000 newborns
- Strategic partnership with NeoPredics strengthens market position
- Integration capabilities with existing hospital EMR systems
- None.
Innovative digital application predicts bilirubin, the biomarker for neonatal jaundice, helping to enhance early intervention and care
Key Benefits of BiliPredics:
- Enhanced Discharge Planning: Supports clinicians to help reduce unnecessary treatments, tests, and extended hospital stays through predictive insights into bilirubin progression.
- Data-Driven Decision Making: Utilizes an extensive database of over 50,000 individual bilirubin measurements of close to 10,000 newborns with a total of about 100,000 individual patient characteristics.
- Integrated Jaundice Management: Helps provide a streamlined pathway for screening, monitoring, and treating neonatal jaundice.
Advanced predictive capabilities
Neonatal jaundice affects approximately
Smooth integration with clinical workflows
BiliPredics requires only a few clinical parameters to generate comprehensive insights. It aligns with established guidelines, including the 2022 AAP Hyperbilirubinemia Guideline, and can integrate with electronic medical records (EMR) to display patient data within the dashboard. The system presents bilirubin trends through comprehensible curves, helping to allow for real-time assessment and intervention.
Strategic partnership to advance neonatal care
"Through our partnership with NeoPredics, we are expanding our offering with an innovative digital solution that strengthens our position as a leader in jaundice management," said Harald Kneuer, director of neonatal care at Dräger. "By combining Dräger's market expertise with NeoPredics' advanced predictive analytics, we are providing healthcare professionals with powerful tools to improve patient outcomes while managing costs."
NeoPredics CEO, Thorsten Waloschek, echoed this sentiment: "Our collaboration with Dräger is a significant milestone in advancing neonatal care. Together, we are bridging innovative technology and clinical expertise to address critical challenges in jaundice management worldwide."
Comprehensive jaundice management solutions
Dräger's neonatal care portfolio includes solutions for both screening and treatment of neonatal jaundice. The Dräger Jaundice Meter JM-105 offers non-invasive, rapid bilirubin measurement, while the BiliLuxTM Phototherapy Light provides effective LED-based phototherapy for jaundice treatment. This approach helps ensure adherence to the latest guidelines, reinforcing the concept of "phototherapy as a drug" with precise irradiance dosing.
About Dräger
Dräger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in 1889, Dräger generated global sales of around
NeoPredics
NeoPredics is a leader in predictive analytics and clinical decision support, with a focus on maternal and neonatal health. Committed to improving outcomes for women and children, NeoPredics develops state-of-the-art solutions like the FDA-registered and CE-certified Bilipredics jaundice management solution, addressing critical challenges in care with innovation and precision. For more information, visit www.neopredics.com
Note: The solution mentioned in this press release will not initially be available in all countries. For more information on the availability of products in your country, please visit the respective country website or contact the local Dräger sales organization.
1Jardine LA, Woodgate P: Neonatal jaundice: phototherapy, ClinicalEvidence 2015;05:319, BMJ Publishing Group
Contact
Communications: Melanie Kamann, Tel. +49 451 882-3202, melanie.kamann@draeger.com
Press Contact North America: Laura Edwards, Tel. +1 215 565-5868, laura.edwards@draeger.com
Investor Relations: Thomas Fischler, Tel. +49 451 882-2685, thomas.fischler@draeger.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/drager-expands-neonatal-care-portfolio-with-bilipredics-software-solution-302406171.html
SOURCE Draeger
FAQ
What is the prediction capability of Dräger's BiliPredics software for neonatal jaundice (DGWPF)?
How does BiliPredics software integrate with existing hospital systems (DGWPF)?
What percentage of newborns can benefit from Dräger's BiliPredics jaundice management system (DGWPF)?
What complementary products does Dräger offer alongside BiliPredics for jaundice management (DGWPF)?
